Recent developments highlight CDT Equity's strategic moves to expand AI capabilities, strengthen intellectual property, and enter new markets through partnerships and licensing.

• In February 2026, CDT Equity announced the acquisition of a 20% stake in Sarborg to expand its AI offerings, enhancing its drug development platform [N1].
• In October 2025, the company executed a 1-for-8 reverse stock split to consolidate its shares [N2].
• In July 2025, Conduit Pharmaceuticals filed its first patent for AZD5658 and new combination patents for AZD1656 and AZD5658 in collaboration with Sarborg Limited, strengthening its intellectual property portfolio [N3].
• In June 2025, the company entered a joint development agreement with Manoira to explore animal health market opportunities, expanding its pipeline applications [N4].
• In May 2025, CDT Equity gained Nasdaq Capital Market approval with transfer effective May 23, and regained compliance with Nasdaq listing requirements, supporting its public market presence [N5][N6].
• In May 2025, the company secured a Korean patent for AZD1656, advancing its global development strategy for autoimmune disorders [N7].
• In April 2025, Andrew Regan was appointed CEO, succeeding David Tapolczay, marking a leadership transition [N8].

CDT Equity leverages advanced AI and solid-form chemistry to unlock value in deprioritized clinical-stage compounds, potentially accelerating drug development and extending patent life. Its strategic partnership with Sarborg Limited enhances its ability to identify novel therapeutic applications and combinations, supported by AI-powered decision tools. The company's pipeline targets multiple therapeutic areas including autoimmune disorders and idiopathic male infertility, with exclusive licenses from AstraZeneca for promising compounds. Collaborations with Manoira Corporation expand its reach into the animal health market, potentially diversifying revenue streams. The company's lean operating model prioritizes capital efficiency and adaptability, focusing on licensing and royalty income rather than costly clinical trials. Recent patent filings and regulatory approvals support its intellectual property and market positioning [N1][N3][N4][N7][S1].

CDT Equity faces significant risks including substantial net losses and limited liquidity, with a current ratio of 0.34 indicating potential short-term financial stress. The company has substantial doubt about its ability to continue as a going concern without raising additional capital, which may not be available on favorable terms or at all. Its reliance on third-party manufacturers and suppliers introduces risks related to supply chain disruptions, regulatory compliance, and quality control. Clinical and pre-clinical trials carry inherent uncertainties, and there is no assurance of successful outcomes or regulatory approvals. The company's business model depends heavily on licensing deals and partnerships, which may be delayed or fail to materialize. Market volatility and economic conditions could further impact its ability to raise funds and operate effectively [S1].

CDT Equity's moat is based on its integration of AI-driven drug repurposing and solid-form chemistry technologies, which aim to extend patent life and improve drug properties for clinical-stage compounds. Its strategic partnerships with Sarborg Limited provide proprietary AI-powered signature analysis and decision-support tools that enhance drug development efficiency and reduce costs. The company's lean, asset-agnostic model allows it to focus capital on high-leverage development strategies rather than costly clinical trials. Exclusive licensing agreements with AstraZeneca for key compounds provide access to assets with existing safety data, potentially reducing development risk. However, the company faces typical biotech risks including clinical trial success uncertainty, reliance on third-party manufacturers, and the need for additional capital to sustain operations.

• Funding and Liquidity Risk: The company has substantial doubt about its ability to continue as a going concern and requires additional capital to fund operations and development. Failure to secure funding could force curtailment or termination of programs.
• Clinical Development Risk: There is no assurance that pre-clinical or clinical trials will be successful, which could delay or prevent commercialization of assets.
• Manufacturing and Supply Chain Risk: CDT relies on third-party manufacturers and suppliers, which may face capacity, quality, regulatory, or financial challenges impacting supply.
• Regulatory and Market Risk: Regulatory approvals are uncertain and may require additional studies. Market acceptance and reimbursement for products are also uncertain.
• Intellectual Property Risk: The company depends on patents and licenses, including those from AstraZeneca and Sarborg collaborations. Challenges to IP rights could adversely affect competitive position.

• CDT Equity Inc., formerly Conduit Pharmaceuticals Inc., is a Delaware corporation focused on data-driven pharmaceutical development leveraging AI, solid-form chemistry, and asset repositioning to develop novel treatments [S1].
• The company targets clinical-stage compounds deprioritized by larger pharmaceutical companies, focusing on compounds with strong Phase I safety data [S1].
• CDT uses advanced co-crystallization and solid-form technologies developed at its Cambridge, UK facility to improve drug properties and extend patent life by up to 20 years [S1].
• The company has a strategic partnership with Sarborg Limited, a related party, to apply AI-powered signature analysis for identifying new therapeutic applications and combinations for existing compounds [S1].
• CDT's pipeline includes candidates targeting autoimmune disorders, idiopathic male infertility, oncology, dermatology, rare diseases, and animal health [S1].
• The company operates a lean, asset-agnostic model prioritizing speed, adaptability, and capital efficiency, avoiding costs of early and late-stage clinical trials [S1].
• CDT holds exclusive rights licensed from AstraZeneca for clinical assets AZD1656, AZD5658, and AZD5904, including rights for idiopathic male infertility indications [S1].
• AZD1656 has undergone Phase I and Phase II clinical trials with no significant safety signals; efficacy showed initial glucose control improvements that diminished over time [S1].
• AZD5658 completed a Phase I study with no deaths or serious adverse events; most adverse events were mild and manageable [S1].
• AZD5904 underwent five Phase I studies with no clinically significant adverse effects reported; it showed potential as a myeloperoxidase inhibitor [S1].
• CDT entered a Services Agreement with Sarborg in December 2024 for algorithmic and cybernetic technology services, including decision-support tools and AI-powered disease mapping; all phases and milestones have been completed [S1].
• The company has an Additional Agreement and subsequent addenda with Sarborg for expanded AI services, including third-party pharma asset analysis and cryptocurrency AI integration [S1].
• CDT has a Joint Development Agreement with Manoira Corporation, a related party, granting a license to evaluate AZD1656 and AZD5658 for animal health applications; Manoira provides data to inform human clinical programs [S1].
• CDT plans to seek exits through third-party license deals following successful pre-clinical trials, focusing on licensing, royalty, or other transactions with third parties for further development and commercialization [S1].
• The company does not currently own manufacturing facilities and relies on third-party suppliers and contract manufacturing organizations for production, testing, and storage [S1].
• CDT's financial snapshot as of December 31, 2025, shows cash and equivalents of $1.509 million, short-term investments of $0.6 million (as of Q1 2025), current assets of $4.379 million, and current liabilities of $12.82 million, resulting in a current ratio of 0.34 and a cash ratio of 0.16 [S1].
• The company reported a net loss of $39.224 million and negative basic and diluted EPS of $-1177.89 per share for the fiscal year ended December 31, 2025 [S1].
• There is substantial doubt about CDT's ability to continue as a going concern without additional funding; the company plans to raise capital through equity sales, debt financing, or strategic collaborations [S1].
• CDT announced a 1-for-8 reverse stock split in October 2025 [N2].
• In February 2026, CDT Equity announced plans to acquire a 20% stake in Sarborg to expand its AI offerings [N1].
• Conduit Pharmaceuticals (former name) filed patents for AZD5658 and combination patents for AZD1656 and AZD5658 in collaboration with Sarborg Limited [N3].
• The company entered a joint development deal with Manoira to enter the animal health market [N4].
• CDT Equity gained Nasdaq Capital Market approval with transfer effective May 23, 2025 [N5].
• Conduit Pharmaceuticals regained compliance with Nasdaq listing requirements in May 2025 [N6].
• The company secured a Korean patent for AZD1656, advancing its global development strategy for autoimmune disorders [N7].
• Andrew Regan was appointed CEO in April 2025, succeeding David Tapolczay [N8].